CoChat

Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome

Open access
Collaud, Fanny, Bortolussi, Giulia, Guianvarc’h, Laurence, Aronson, Sem J., Bordet, Thierry, Veron, Philippe, Charles, Severine, Vidal, Patrice, Sola, Marcelo Simon, Rundwasser, Stephanie, Dufour, Delphine G., Lacoste, Florence, Luc, Cyril, Wittenberghe, Laetitia v., Martin, Samia, Le Bec, Christine, Bosma, Piter J., Muro, Andres F., Ronzitti, Giuseppe, Hebben, Matthias, Mingozzi, Federico · 2019 · Molecular Therapy - Methods & Clinical Development
Cited by 63

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Adeno-associated viruses (AAVs) are among the most efficient vectors for liver gene therapy. Results obtained in the first hemophilia clinical trials demonstrated the long-term efficacy of this approach in humans, showing efficient targeting of hepatocytes with both self-complementary (sc) and single-stranded (ss) AAV vectors. However, to support clinical development of AAV-based gene therapies, efficient and scalable production processes are needed. In an effort to translate to the clinic an approach of AAV-mediated liver gene transfer to treat Crigler-Najjar (CN) syndrome, we developed an (ss)AAV8 vector carrying the human UDP-glucuronosyltransferase family 1-member A1 (hUGT1A1) transgene under the control of a liver-specific promoter. We compared our construct with similar (sc)AAV8 vectors expressing hUGT1A1, showing comparable potency in vitro and in vivo . Conversely, (ss)AAV8-hUGT1A1 vectors showed superior yields and product homogeneity compared with their (sc) counterpart. We then focused our efforts in the scale-up of a manufacturing process of the clinical product (ss)AAV8-hUGT1A1 based on the triple transfection of HEK293 cells grown in suspension. Large-scale production of this vector had characteristics identical to those of small-scale vectors produced in adherent cells. Preclinical studies in animal models of the disease and a good laboratory practice (GLP) toxicology-biodistribution study were also conducted using large-scale preparations of vectors. These studies demonstrated long-term safety and efficacy of gene transfer with (ss)AAV8-hUGT1A1 in relevant animal models of the disease, thus supporting the clinical translation of this gene therapy approach for the treatment of CN syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2018.12.011

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 28

  1. Crigler, 1952, Congenital familial nonhemolytic jaundice with kernicterus, Pediatrics, 10, 169
  2. Arias, 1969, Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity, Am. J. Med., 47, 395, 10.1016/0002-9343(69)90224-1 · DOI · Paper page
  3. Tu, 2012, Liver transplantation in Crigler-Najjar syndrome type I disease, HBPD INT, 11, 545
  4. Lysy, 2008, Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives, World J. Gastroenterol., 14, 3464, 10.3748/wjg.14.3464 · DOI
  5. Hafkamp, 2007, Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial, Pediatr. Res., 62, 725, 10.1203/PDR.0b013e3181598cc5 · doi:10.1203/pdr.0b013e3181598cc5
  6. van der Veere, 1996, Current therapy for Crigler-Najjar syndrome type 1: report of a world registry, Hepatology, 24, 311, 10.1002/hep.510240205 · DOI · Paper page
  7. Fagiuoli, 2013, Monogenic diseases that can be cured by liver transplantation, J. Hepatol., 59, 595, 10.1016/j.jhep.2013.04.004 · DOI · Paper page
  8. Junge, 2015, Adeno-associated virus vector-based gene therapy for monogenetic metabolic diseases of the liver, J. Pediatr. Gastroenterol. Nutr., 60, 433, 10.1097/MPG.0000000000000703 · DOI
  9. Bortolussi, 2018, Advances in understanding disease mechanisms and potential treatments for Crigler–Najjar syndrome, Expert Opin. Orphan Drugs, 6, 425, 10.1080/21678707.2018.1495558 · DOI
  10. George, 2017, Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant, N. Engl. J. Med., 377, 2215, 10.1056/NEJMoa1708538 · DOI · Paper page
  11. Bortolussi, 2012, Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer, FASEB J., 26, 1052, 10.1096/fj.11-195461 · DOI
  12. Bortolussi, 2014, Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome, Hum. Gene Ther., 25, 844, 10.1089/hum.2013.233 · DOI · Paper page
  13. Seppen, 2006, Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats, Mol. Ther., 13, 1085, 10.1016/j.ymthe.2006.01.014 · DOI · Paper page
  14. Ronzitti, 2016, A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome, Mol. Ther. Methods Clin. Dev., 3, 16049, 10.1038/mtm.2016.49 · DOI · Paper page
  15. 2016, Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015, Lancet HIV, 3, e361, 10.1016/S2352-3018(16)30087-X · DOI · Paper page
  16. Nathwani, 2006, Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver, Blood, 107, 2653, 10.1182/blood-2005-10-4035 · DOI · Paper page
  17. Gunn, 1944, Hereditary Acholuric Jaundice in the Rat, Can. Med. Assoc. J., 50, 230
  18. Cornelius, 1972, Animal model of human disease. Crigler-Najjar Syndrome. Animal model: hereditary nonhemolytic unconjugated hyperbilirubinemia in Gunn rats, Am. J. Pathol., 69, 369
  19. Sato, 1991, Genetic defect of bilirubin UDP-glucuronosyltransferase in the hyperbilirubinemic Gunn rat, Biochem. Biophys. Res. Commun., 177, 1161, 10.1016/0006-291X(91)90661-P · doi:10.1016/0006-291x(91)90661-p
  20. D’Avola, 2016, Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria, J. Hepatol., 65, 776, 10.1016/j.jhep.2016.05.012 · DOI · Paper page
  21. Chahal, 2014, Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery, J. Virol. Methods, 196, 163, 10.1016/j.jviromet.2013.10.038 · DOI · Paper page
  22. Wright, 2014, AAV empty capsids: for better or for worse?, Mol. Ther., 22, 1, 10.1038/mt.2013.268 · DOI · Paper page
  23. Favaro, 2009, Host and vector-dependent effects on the risk of germline transmission of AAV vectors, Mol. Ther., 17, 1022, 10.1038/mt.2009.56 · DOI · Paper page
  24. Davidoff, 2005, Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models, Mol. Ther., 11, 875, 10.1016/j.ymthe.2004.12.022 · DOI · Paper page
  25. Snyder, 1997, Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice, Hum. Gene Ther., 8, 1891, 10.1089/hum.1997.8.16-1891 · DOI · Paper page
  26. Thummel, 1982, Construction of adenovirus expression vectors by site-directed in vivo recombination, J. Mol. Appl. Genet., 1, 435
  27. Meliani, 2017, Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors, Blood Adv., 1, 2019, 10.1182/bloodadvances.2017010181 · DOI · Paper page
  28. Montenegro-Miranda, 2013, Adeno-associated viral vector serotype 5 poorly transduces liver in rat models, PLoS ONE, 8, e82597, 10.1371/journal.pone.0082597 · DOI

Cited by

See all 63

Metadata

Authors
Collaud, F., Bortolussi, G., Guianvarc’h, L., Aronson, S. J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M. S., Rundwasser, S., Dufour, D. G., Lacoste, F., Luc, C., Wittenberghe, L. V., Martin, S., Le Bec, C., Bosma, P. J., Muro, A. F., Ronzitti, G., Hebben, M., & Mingozzi, F.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2019-03
Volume
12
Pages
157-174
ISSN
2329-0501 (ISSN-L)
OpenAlex
W2907308363
Cited by
63
References
18
FWCI
2.78
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • European Union’s H2020 (755225)
  • Genethon
  • Association Française contre les Myopathies
  • CIAMI Association of Crigler-Najjar patients Italy
  • Conseil Départemental de l'Essonne
  • ZonMW TGO
  • Najjar Fund
  • Beneficentia Stiftung
  • EU Marie Slodowska-Curie (658712-3)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. https://app.cochat.ai/papers/10.1016/j.omtm.2018.12.011
The paper
Collaud, F., Bortolussi, G., Guianvarc’h, L., Aronson, S. J., Bordet, T., Veron, P., Charles, S., Vidal, P., Sola, M. S., Rundwasser, S., Dufour, D. G., Lacoste, F., Luc, C., Wittenberghe, L. V., Martin, S., Le Bec, C., Bosma, P. J., Muro, A. F., Ronzitti, G., . . . Mingozzi, F. (2019). Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2018.12.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.